Are there any risks or uncertainties highlighted in the release that could affect the stock's volatility in the short term?

Short‑term volatility drivers

The release is overwhelmingly positive – it highlights “strong commercial momentum” and re‑affirms the 2025 guidance. However, the company’s upside is still hinged on a handful of clinical‑development milestones that are not detailed in the statement (e.g., the timing of key immunotherapy read‑outs, regulatory filings and any potential trial‑design changes). Those milestones are the primary source of short‑term risk: a delay, a partial‑failure, or an unexpected safety signal can quickly reverse the market’s optimism and trigger a spike in volatility. In addition, the company continues to operate at a cash‑burn rate typical for early‑stage oncology firms, so any short‑term cash‑flow shortfall or need to raise capital could add another layer of uncertainty.

Trading implications

While the earnings beat and reaffirmed guidance should support the stock in the near term, traders should keep a tight watch on:

• Upcoming data releases or FDA interactions – any deviation from the expected timeline can act as a catalyst.
  
• Cash‑runway updates – if the company signals a need for additional financing, the share price could react sharply.
  

Given the lack of explicit risk disclosures in the release, the short‑term risk profile is latent rather than overt. A prudent approach is to stay positioned with a modest exposure, set a tight stop‑loss to guard against an unexpected clinical setback, and monitor the company’s pipeline‑update calendar for any events that could reignite volatility.